Airborne Particulate Matter Size and Chronic Obstructive Pulmonary Disease Exacerbations: A Prospective, Risk-Factor Analysis Comparing Global Initiative for Obstructive Lung Disease 3 and 4 Categories
-
Published:2023-10-18
Issue:10
Volume:13
Page:1505
-
ISSN:2075-4426
-
Container-title:Journal of Personalized Medicine
-
language:en
-
Short-container-title:JPM
Author:
Bălă Gabriel-Petrică12, Rosca Ovidiu3, Bratosin Felix23ORCID, Shetty Uday Shree Akkala4, Vutukuru Sai Diksha5, Sanda Isabella-Ionela2, Marc Monica16ORCID, Fira-Mladinescu Ovidiu16ORCID, Oancea Cristian26ORCID
Affiliation:
1. Center for Research and Innovation in Precision Medicine of Respiratory Diseases, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania 2. Doctoral School, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania 3. Department of Infectious Diseases, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania 4. Malla Reddy Institute of Medical Sciences, Suraram Main Road 138, Hyderabad 500055, India 5. Department of General Medicine, MNR Medical College, Hyderabad 502285, India 6. Discipline of Pulmonology, “Victor Babes” University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania
Abstract
Current research primarily emphasizes the generalized correlations between airborne pollution and respiratory diseases, seldom considering the differential impacts of particular particulate matter sizes on chronic obstructive pulmonary disease (COPD) exacerbations in distinct Global Initiative for Obstructive Lung Disease (GOLD) categories. This study hypothesizes a critical association between particulate matter sizes (PM 1.0, PM 2.5, and PM 10) and exacerbation frequency in COPD patients categorized under GOLD 3 and GOLD 4, with a potential augmenting role played by proximity to main roads and industrial areas. This research aspires to offer a nuanced perspective on the exacerbation patterns in these groups, setting the stage for targeted intervention strategies. Utilizing a prospective design, this study followed 79 patients divided into GOLD 3 (n = 47) and GOLD 4 (n = 32) categories. The participants were monitored for ten days for daily activity levels, symptoms, living conditions, and airborne particulate matter concentrations, with spirometric evaluations employed to measure lung function. Statistical analyses were used to identify potential risk factors and significant associations. The analysis revealed substantial disparities in airborne particulate matter sizes between the two groups. The mean PM 1.0 concentration was notably higher in GOLD 4 patients (26 µg/m3) compared to GOLD 3 patients (18 µg/m3). Similarly, elevated PM 2.5 levels were observed in the GOLD 4 category (35 µg/m3) in contrast to the GOLD 3 category (24 µg/m3). A vital finding was the increased frequency of exacerbations in individuals residing within 200 m of main roads compared to those living further away (OR = 2.5, 95% CI: 1.5–4.1). Additionally, patients residing in homes smaller than 50 square meters demonstrated a greater frequency of exacerbations. Spirometry results corroborated the exacerbated condition in GOLD 4 patients, indicating a significant decline in lung function parameters compared to the GOLD 3 group. This study substantiates a significant association between airborne particulate matter sizes and exacerbation frequencies in COPD patients, particularly accentuating the increased risk in GOLD 4 patients. Our findings underscore the pivotal role of environmental factors, including the size of living areas and proximity to main roads, in influencing COPD exacerbations. These results suggest the need for personalized healthcare strategies and interventions, which account for environmental risk factors and the distinctions between GOLD 3 and GOLD 4 categories of COPD patients.
Subject
Medicine (miscellaneous)
Reference42 articles.
1. Chronic obstructive pulmonary disease: An overview;Devine;Am. Health Drug Benefits,2008 2. Barata, P.I., Crisan, A.F., Maritescu, A., Negrean, R.A., Rosca, O., Bratosin, F., Citu, C., and Oancea, C. (2022). Evaluating Virtual and Inpatient Pulmonary Rehabilitation Programs for Patients with COPD. J. Pers. Med., 12. 3. An overview of exacerbations of chronic obstructive pulmonary disease: Can tests of small airways’ function guide diagnosis and management?;Alobaidi;Ann. Thorac. Med.,2020 4. Acute exacerbations of chronic obstructive pulmonary disease: In search of diagnostic biomarkers and treatable traits;Mathioudakis;Thorax,2020 5. Pescaru, C.C., Crisan, A.F., Marc, M., Trusculescu, A.A., Maritescu, A., Pescaru, A., Sumenkova, A., Bratosin, F., Oancea, C., and Vastag, E. (2023). A Systematic Review of Telemedicine-Driven Pulmonary Rehabilitation after the Acute Phase of COVID-19. J. Clin. Med., 12.
|
|